title: Characterization of a putative filovirus vaccine: virus-like particles.
abstract: Filoviruses are hemorrhagic fever viruses endemic to parts of Africa and the Philippines. Infection carries with it a mortality rate of up to 90% and currently there are no effective vaccines or therapeutics available to combat infection. However, the filovirus virus-like particles (VLP), which are currently under development, have been shown to be a promising vaccine candidate. They provide protection from infection in the mouse, guinea pig, and nonhuman primate models of infection, eliciting high anti-glycoprotein antibody titers and T cell responses to viral proteins. In this review, we will highlight the development of the filovirus VLP and describe the current understanding of VLP immunogenicity and correlates of protection.
authors: US Army Medical Research Institute of Infectious Diseases, 1425 Porter St., Fort Detrick, MD 21702, USA. karen.a.oconnell.ctr@us.army.mil
authors: Karen A O
authors: KA
authors: Martins
authors: Travis K
authors: TK
authors: Warren
authors: Sina
authors: S
authors: Bavari
mesh_terms: D000818:Animals; D016563:Filoviridae / Q000276:immunology* / Q000472:pathogenicity; D018702:Filoviridae Infections / Q000276:immunology* / Q000517:prevention & control*; D058425:Vaccines, Virus-Like Particle / Q000276:immunology* / Q000627:therapeutic use; D014765:Viral Vaccines / Q000276:immunology* / Q000627:therapeutic use
chemical_list: D058425:Vaccines, Virus-Like Particle; D014765:Viral Vaccines
references: Wkly Epidemiol Rec. 2012 Nov 2;87(44):421
references: 23139950
references: J Virol. 2006 Jun;80(11):5168-78
references: 16698997
references: J Virol. 2005 Aug;79(16):10442-50
references: 16051836
references: J Exp Med. 2004 Jul 19;200(2):169-79
references: 15249592
references: Wkly Epidemiol Rec. 2012 Oct 26;87(43):414
references: 23113326
references: PLoS Negl Trop Dis. 2011 Oct;5(10):e1359
references: 22028943
references: J Virol. 2004 Jul;78(14):7344-51
references: 15220407
references: Arch Virol Suppl. 1993;7:81-100
references: 8219816
references: Hum Vaccin. 2011 Jun;7(6):701-11
references: 21519188
references: J Virol. 2005 Feb;79(4):2413-9
references: 15681442
references: J Infect Dis. 2007 Nov 15;196 Suppl 2:S421-9
references: 17940979
references: Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3974-9
references: 18305167
references: Vaccine. 2004 Sep 3;22(25-26):3495-502
references: 15308377
references: PLoS Pathog. 2009 Jun;5(6):e1000493
references: 19557165
references: J Immunol. 2005 Jul 15;175(2):1184-91
references: 16002721
references: FEMS Immunol Med Microbiol. 2004 Jan 15;40(1):27-31
references: 14734183
references: J Interferon Cytokine Res. 2009 Sep;29(9):511-20
references: 19694547
references: Vaccine. 2005 Apr 27;23(23):3033-42
references: 15811650
references: J Exp Med. 2002 Mar 4;195(5):593-602
references: 11877482
references: J Infect Dis. 2011 Nov;204 Suppl 3:S871-7
references: 21987763
references: Virology. 2004 Sep 1;326(2):280-7
references: 15302213
references: Nat Rev Microbiol. 2009 May;7(5):393-400
references: 19369954
references: Immunol Cell Biol. 2011 Oct;89(7):792-802
references: 21263462
references: J Infect Dis. 2007 Nov 15;196 Suppl 2:S430-7
references: 17940980
references: Clin Vaccine Immunol. 2008 Mar;15(3):460-7
references: 18216185
references: Virology. 2007 Aug 1;364(2):342-54
references: 17434557
references: J Am Vet Med Assoc. 2009 May 1;234(9):1130-9
references: 19405883
references: Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15889-94
references: 14673108
references: J Virol. 2003 Sep;77(18):9987-92
references: 12941909
references: J Infect Dis. 1998 Sep;178(3):651-61
references: 9728532
references: J Infect Dis. 2003 Dec 1;188(11):1630-8
references: 14639532
references: Virol J. 2006 May 23;3:31
references: 16719918